IPO calendar HERE includes analyst report expectations for subscribers:
Ranked by IPO Size
(1) Based in Alameda, CA, Penumbra (PEN) scheduled a $101 million IPO on NYSE with a market capitalization of $791 million at a price range midpoint of $26.50 for Friday, Sept. 18, 2015.
Penumbra is a global interventional therapies company that designs, develops, manufactures and markets innovative medical devices.
PEN has a broad portfolio of products that addresses challenging medical conditions and significant clinical needs across two major markets, neuro and peripheral vascular.
(2) Based in Rockville, MD, REGENXBIO Inc. (RGNX) scheduled a $100 million IPO on Nasdaq with a market capitalization of $443 million at a price range midpoint of $18 for Thursday, Sept. 17, 2015.
RGNX is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy.
Approximately 70% of all AAV gene therapy clinical trials relating to new treatment Investigational New Drug applications (INDs) posted on the United States government clinical trials database from 2012 through 2014 used NAV Vectors.
(3) Based in Vienna, Austria, Nabriva Therapeutics AG (NBRV) scheduled a $96 million IPO on Nasdaq with a market capitalization of $268 million at a price range midpoint of $18 for Friday, Sept. 18, 2015.
NBRV is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics.
NBRV is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer